Citations 400
Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
Ghorab, Ahmad , Litzow, Mark R. , Gangat, Naseema , Al‐Kali, Aref , Tefferi, Ayalew , Begna, Kebede H. , Patnaik, Mrinal M. , Foran, James M. , Ghorab, Ahmad , Shah, Meera , Murthy, Hemant S. , Alkhateeb, Hassan B. , Badar, Talha
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020
Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
Ilyas, Rimal, Johnson, Isla McKerrow , Al‐Kali, Aref , Begna, Kebede, Mangaonkar, Abhishek A. , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Tefferi, Ayalew, Gangat, Naseema , McCullough, Kristen , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera , Tefferi, Ayalew
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287
Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia
Litzow, Mark R. , Gangat, Naseema , Al‐Kali, Aref , Foran, James M. , Palmer, Jeanne , Mangaonkar, Abhishek A. , McCullough, Kirsten, Tefferi, Ayalew , Patnaik, Mrinal M. , Csizmar, Clifford M. , Saliba, Antoine N. , Hogan, William J. , McCullough, Kirsten, Alkhateeb, Hassan B.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12238-12240
The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
Smith, Alexandra N., Ali, Najla Al , Coombs, Catherine C. , Foran, James M. , Tsai, Charlton , Amanam, Idoroenyi , Lai, Catherine , Deeg, Joachim, Dinner, Shira, Chandhok, Namrata S. , Soong, Deborah, Brunner, Andrew M. , Geyer, Susan M. , Padron, Eric , Patnaik, Mrinal M. , Al‐Kali, Aref , Xie, Zhuoer , Komrokji, Rami S. , Patel, Anand , Saygin, Caner , Zeidan, Amer M. , Bewersdorf, Jan Philipp , Kishtagari, Ashwin , Zeidner, Joshua F. , Madanat, Yazan F. , Badar, Talha , Desai, Pinkal , Griffiths, Elizabeth A. , Malki, Monzr M. Al , Lai, Catherine, Adès, Lionel , Yi, Cecilia Arana , Osman, Afaf E.G. , Abaza, Yasmin , Taylor, Justin , Carraway, Hetty E. , Singh, Abhay , Savona, Michael R.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2887-2890
Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
Abdelmagid, Maymona, Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Elliott, Michelle A. , Howard, Matthew O. , Reichard, Kaaren K. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew , Hogan, William J. , Alkhateeb, Hassan B. , Shi, Min , Howard, Matthew, Ketterling, Rhett P.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9735-9736
Prevalence and Impact of Clonal Hematopoiesis in Therapy Related Myeloid Neoplasms Occurring in the Context of Low-Grade Follicular Lymphoma Treated with Radioisotope Therapy
Lasho, Terra, Khurana, Arushi , Finke, Christy M. , Mangaonkar, Abhishek A. , Ansell, Stephen M. , Al‐Kali, Aref , Gangat, Naseema , Abeykoon, Jithma P. , Patnaik, Mrinal M. , Xie, Zhuoer , Ferrer, Alejandro , Fernandez, Jenna , Shah, Meera , Witzig, Thomas E.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11403-11405
U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations
Pritzl, Stephanie , Lasho, Terra, Finke, Christy M. , Mangaonkar, Abhishek A. , Gangat, Naseema , Al‐Kali, Aref , Viswanatha, David S., He, Rong, Foran, James M. , Patnaik, Mrinal M. , Badar, Talha , Ferrer, Alejandro , McCullough, Kristen , Fernandez, Jenna , He, Rong
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11408-11409
Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
Ladon, Dariusz, Chhetri, Rakchha , Sharplin, Kirsty, Al‐Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Kebede, Ashanka Begna, Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Tefferi, Ayalew , Kok, Chung Hoow , Tran, Elizabeth Ngoc Hoa , Baranwal, Anmol , Alkhateeb, Hassan B. , Singhal, Deepak , Yeung, David , Ross, David M , Hogan, William J. , Shanmuganathan, Naranie , Kumar, Sharad , THOMAS, DANIEL W. , Shah, Meera , Hiwase, Devendra
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6962-6963
Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
Chhetri, Rakchha , Al‐Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Begna, Kebede, Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Singhal, Deepak , Hogan, William J. , Kutyna, Monika , Alkhateeb, Hassan B. , Baranwal, Anmol , Shanmuganathan, Naranie , Kumar, Sharad , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965
ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
Garcia‐Manero, Guillermo , Bachiashvili, Kimo, Amin, Harshad, Sallman, David A. , Al‐Kali, Aref , Cripe, Larry D., Sano, Yuri, Oganesian, Aram , Yacoub, Abdulraheem , Traer, Elie , Pollyea, Daniel Aaron , Berdeja, Jesús G. , Griffiths, Elizabeth A. , Mohan, Sanjay , Keer, Harold N
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1112-1114